Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132295) titled 'An open-label, multicenter, phase II clinical study to evaluate the safety, efficacy and pharmacokinetics of TT00420 tablets combined with novel endocrine therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after prior treatment' on Sept. 11.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Condition:
Metastatic castration-resistant prostate cancer
Intervention:
Cohort A1:TT-00420 tablets 10 mg QD + darolutamide
Cohort A2:TT-00420 tablets 10 mg QD (2 weeks on / 1 week off) + darolutamide...